Dose Escalation of Subcutaneous Epcoritamab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Lancet 2021 Sep 08;[EPub Ahead of Print], M Hutchings, R Mous, MR Clausen, P Johnson, KM Linton, MED Chamuleau, DJ Lewis, A Sureda Balari, D Cunningham, RS Oliveri, B Elliott, D DeMarco, A Azaryan, C Chiu, T Li, KM Chen, T Ahmadi, PJ LugtenburgFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.